Apellis Pharmaceuticals
Focus: Apellis is a specialty pharmaceutical company focused on complement inhibitor therapeutics, headquartered in Australia with a commercial-heavy footprint. The company derives 94% of revenue from EMPAVELI (pegcetacoplan), a complement inhibitor approved for multiple indications.
Profile data last refreshed 9h ago · AI intelligence enriched 2w ago
Open Jobs
16-9 this month
Cooling — net -9 jobs in 30d
5 added, 14 removed. Slower than typical.
Should You Work at Apellis Pharmaceuticals?
AI assessmentA commercially focused opportunity with stable near-term revenue but concentrated bet-the-company risk; best for sales/market access professionals seeking established product momentum.
Why Work Here
- EMPAVELI and SYFOVRE are in peak revenue phase with patent protection until 2038, providing revenue stability and long runway for career development.
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$25M Part DStable
Peak
Help build intelligence for Apellis Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.